Diagnostic Workup for Perinephric Hemorrhagic Cysts
Initial Evaluation
- Patients with suspected perinephric hemorrhagic cysts typically present with sudden, severe abdominal or flank pain, which occurs in approximately 80% of cases 2
- Initial screening should include ultrasound examination, which may show heterogeneous hyperechoic and mobile material (clots) and thin mobile septations within the cyst 1, 2
Imaging Protocol
- Ultrasound is the first-line imaging modality for initial screening 1
- On ultrasound, look for debris with thick wall and/or distal acoustic enhancement 1, heterogeneous hyperechoic and mobile material corresponding to clots 2, and thin mobile septations 2
- MRI is very specific for hemorrhagic cysts and should be the primary diagnostic tool 1, 2
- Key MRI findings include hyperintensity on both T1- and T2-weighted sequences 1, heterogeneous signal on T1-weighted sequences 1, thickened wall and fluid-fluid level (blood-filled lakes between septa) 1, and high signal intensity on diffusion-weighted images 1
- CT is not recommended to diagnose cyst hemorrhage (strong recommendation, 91% consensus) 1, 2
- CT may be useful to detect wall calcifications that may ensue after cyst hemorrhage 1 and to evaluate for possible malignancy when suspected 3
Differential Diagnosis Considerations
- Differentiate from infected cysts, which may show enhanced wall thickening and/or perilesional inflammation 1, gas within the cyst 1, increased FDG activity on PET-CT 1, and clinical signs of infection (fever, increased WBC, increased CRP) 1
- Differentiate from malignant cystic lesions, which may have round mural nodules (some enhancing) that can mimic malignancy 1
Management Considerations
- Conservative management is preferred for hemorrhagic cysts 2
- Interventions such as aspiration or laparoscopic deroofing should be avoided during active hemorrhage 2
- For patients on anticoagulants, consider temporary discontinuation for 7-15 days after onset of hemorrhage 2 and interrupting aspirin for 3 days for patients on antiplatelet therapy 4